Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Gains from Investment Securities (2017 - 2025)

Moleculin Biotech (MBRX) has 10 years of Gains from Investment Securities data on record, last reported at -$560000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$560000.0; the TTM value through Sep 2025 reached -$10.2 million, down 1007.95%, while the annual FY2024 figure was $784528.0, 24.85% down from the prior year.
  • Gains from Investment Securities reached -$560000.0 in Q3 2025 per MBRX's latest filing, up from -$9.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.8 million in Q3 2021 and bottomed at -$9.6 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is -$459101.2, with a median of -$1000.0 recorded in 2021.
  • Peak YoY movement for Gains from Investment Securities: surged 13770.0% in 2021, then crashed 219.38% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$1000.0 in 2021, then tumbled by 42000.0% to -$421000.0 in 2022, then skyrocketed by 366.03% to $1.1 million in 2023, then dropped by 29.95% to $784528.0 in 2024, then tumbled by 171.38% to -$560000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$560000.0 in Q3 2025, -$9.6 million in Q2 2025, and $784528.0 in Q4 2024.